Tasly Pharmaceutical

Tasly Pharmaceutical is a Chinese pharmaceutical company associated with the Tasly healthcare group and headquartered in Tianjin. The business developed around the combination of traditional Chinese medicine, pharmaceutical manufacturing, modern quality-control systems, and research intended to translate established Chinese formulations into standardized dosage forms. Its best-known product is Compound Danshen Dripping Pills, a cardiovascular medicine derived from a traditional formulation and marketed in China for coronary heart disease-related indications. The product has also been the focus of international regulatory and clinical-development efforts. The company was founded in 1994 by Yan Xijun and became one of the more prominent corporate representatives of China's modern traditional-Chinese-medicine sector. Rather than presenting traditional medicine solely through raw herbs or hospital decoctions, Tasly emphasized industrial production, proprietary formulations, extraction and processing technology, quality standards, and branded pharmaceutical distribution. This approach helped position the company between a conventional Chinese patent-medicine producer and a research-oriented pharmaceutical enterprise. Tasly's business scope has extended beyond a single medicine. Its activities have included prescription and over-the-counter medicines, traditional Chinese medicines, chemical pharmaceuticals, health products, botanical and natural-product research, pharmaceutical production services, and international regulatory development. The broader Tasly group has also operated in areas such as healthcare services, biotechnology, wellness, and related consumer-health businesses. The pharmaceutical company remains most closely identified with medicines produced under the Tasly name rather than with the group's broader portfolio. A major strategic theme has been the modernization and internationalization of traditional Chinese medicine. Tasly has invested in research facilities, clinical studies, manufacturing capacity, and regulatory submissions in an effort to make selected traditional formulations more compatible with evidence-based pharmaceutical standards. Its international work has included development activity in the United States and other markets, although regulatory progress and commercial availability have varied by jurisdiction. Compound Danshen Dripping Pills became a prominent example of both the opportunity and difficulty involved in taking a traditional Chinese medicine through modern foreign drug-approval systems. Tasly was historically a Shanghai-listed company under the ticker 600535. Public reporting has also described changes in the relationship between the listed pharmaceutical company and Tasly Holding Group, including ownership and privatization-related developments. Because the precise current listing and ownership position can change through corporate transactions, the latest exchange filings should be consulted before using the company as a current public-market reference. The brand's positioning combines Chinese medical heritage with industrial pharmaceutical presentation. Its communications typically emphasize the scientific development, standardized manufacture, and clinical application of traditional formulations rather than treating tradition alone as the product proposition. Tasly therefore occupies a distinctive position in China's healthcare market: it is a pharmaceutical brand rooted in traditional Chinese medicine but organized around modern corporate research, manufacturing, distribution, and regulatory practices. Tasly Medical is the medical and pharmaceutical identity associated with Tasly Pharmaceutical Group, a Chinese healthcare company headquartered in Tianjin. The group is particularly associated with the development, manufacture, and commercialization of traditional Chinese medicines, while also operating in chemical pharmaceuticals, biological products, health products, and related medical and healthcare activities. Because “Tasly Medical” is not clearly established as a separately incorporated global consumer brand, the name is best treated as a brand or business identity connected with the broader Tasly group rather than as an independently documented company. Tasly emerged in the 1990s during a period when Chinese pharmaceutical companies were modernizing traditional Chinese medicine through standardized extraction, pharmaceutical quality systems, clinical research, and large-scale industrial production. Its best-known product association is Compound Danshen Dripping Pills, a cardiovascular medicine based on traditional Chinese medicinal ingredients. The product became a prominent example of an attempt to present a traditional formulation in a modern dosage form and to support it with contemporary pharmaceutical development and clinical evidence. Tasly’s wider portfolio has included proprietary Chinese medicines, prescription and over-the-counter medicines, health products, and other pharmaceutical products. The company’s business model has historically combined research and development, cultivation or sourcing of medicinal materials, pharmaceutical production, distribution, brand building, and medical or health-related services. Its traditional Chinese medicine activities have been supported by manufacturing facilities and research programs intended to improve consistency, quality control, dosage, and regulatory acceptance. At the same time, the group has pursued diversification beyond a single traditional medicine product, including chemical drugs, biological medicines, healthcare products, and international regulatory development. Tasly’s international profile has been linked mainly to efforts to register or commercialize selected products outside mainland China, especially its cardiovascular medicine. Such efforts have faced the evidentiary and regulatory requirements applicable to pharmaceutical products in overseas markets. The group’s presence should therefore not be interpreted as equivalent to that of a universally distributed consumer healthcare brand. The Tasly name is also associated with a wider corporate group whose activities have extended beyond pharmaceuticals into healthcare, biotechnology, medical services, and other health-related businesses. The precise relationship between “Tasly Medical,” “Tasly,” and individual Tasly legal entities can vary by market and document. This dossier consequently describes the subject as the healthcare brand identity of the Tasly pharmaceutical organization and avoids assigning unsupported standalone ownership, management, or financial details to “Tasly Medical” itself. Tasly remains active in China’s pharmaceutical and traditional Chinese medicine sectors. Its significance lies in its role in industrializing proprietary Chinese medicines, building nationally recognized pharmaceutical brands, and attempting to connect traditional medical knowledge with modern formulation, manufacturing, clinical development, and regulatory practices. Tasly Group is a Chinese healthcare enterprise associated primarily with the modernization and commercialization of traditional Chinese medicine. Established in Tianjin in 1994, the group developed from a pharmaceutical business into a broader healthcare platform spanning traditional Chinese medicines, chemical and biological drugs, health products, medical services, and international operations. Its identity is closely linked to the attempt to combine traditional formulations and diagnostic concepts with standardized manufacturing, pharmaceutical research, quality control, and modern brand management. The group is best known internationally for Compound Danshen Dripping Pill, a traditional Chinese medicine product used in China in connection with cardiovascular conditions. The product became an important symbol of Tasly's strategy: take a widely used traditional formulation, produce it in a standardized dosage form, and seek evidence and regulatory recognition in overseas markets. Tasly's broader portfolio has included proprietary Chinese medicines, prescription and over-the-counter medicines, nutritional products, and consumer health offerings. The exact composition of the portfolio has changed over time as the group has reorganized businesses and adjusted its focus. Tasly's corporate structure has included both privately controlled holding activities and publicly traded pharmaceutical operations. Tasly Pharmaceutical Group Co., Ltd. has functioned as a major listed operating company associated with the Tasly name, while the wider group has extended beyond a single listed entity. This distinction is important: Tasly Group is a corporate healthcare group and brand family, whereas Tasly Pharmaceutical Group is a particular operating company within the broader corporate structure. The company has invested in research and development, production facilities, cultivation and sourcing of medicinal materials, manufacturing technology, and international regulatory work. Its business model has combined established traditional Chinese medicine products with new drug development and health-related consumer products. The group has also promoted the use of modern extraction, formulation, quality-management, and clinical-evaluation methods to support the credibility and scalability of traditional medicines. Tasly's public profile has been strongest in China, where its products have been distributed through pharmaceutical, medical, and consumer-health channels. It has also pursued overseas distribution and regulatory projects, although the availability and regulatory status of individual products differ by country. International expansion has therefore been more complex than simple retail export: pharmaceutical registration, clinical evidence, quality standards, and local rules have all affected the group's ability to commercialize products outside China. In strategic terms, Tasly occupies the intersection of traditional Chinese medicine, conventional pharmaceuticals, and consumer healthcare. Its positioning emphasizes integration rather than a purely traditional or purely biomedical identity. The group remains active, but details concerning current ownership, executive leadership, operating subsidiaries, and the status of specific international programs should be checked against current company disclosures before publication. Tasly is a Chinese pharmaceutical and health-care brand headquartered in Tianjin. Founded in 1994 by Yan Xijun, it began with the modernization of traditional Chinese medicine and developed into a diversified life-and-health enterprise covering modern traditional Chinese medicines, biopharmaceuticals, chemical drugs, health products, medical services and selected investment businesses. Its principal listed operating company is Tasly Pharmaceutical Group Co., Ltd., which trades on the Shanghai Stock Exchange under ticker 600535.SS. The company’s identity is closely associated with the industrialization of traditional Chinese medicine. Rather than positioning TCM solely as a heritage or wellness category, Tasly has emphasized standardized raw materials, controlled manufacturing, dosage-form innovation, clinical research, quality systems and international regulatory work. Its best-known product is Compound Danshen Dripping Pills, marketed internationally under the Dantonic brand. The formulation is used in the cardiovascular field and has been the subject of a long-running development and regulatory program in the United States. Tasly’s modern-TCM portfolio also includes Yangxue Qingnao products, Qishen Yiqi Dripping Pills and Yiqi Fumai for Injection. Tasly’s pharmaceutical portfolio extends beyond TCM. The group has developed or commercialized biopharmaceuticals such as recombinant human prourokinase for injection, a thrombolytic product, and chemical medicines including temozolomide, eszopiclone and tadalafil. Company materials describe a therapeutic focus on cardiovascular and metabolic disease, digestive disease, oncology and immunology, and neurological or psychiatric conditions. Its research model combines internal discovery, cooperative development, product licensing, acquisitions and commercialization partnerships. Internationalization has been a recurring strategic theme. Tasly established Tasly Pharmaceuticals, Inc. in the United States in 2006 to support clinical research, regulatory affairs, technical cooperation and overseas business development. The group has also pursued international research and commercialization arrangements, including a 2015 cooperation agreement concerning T89, the development code for Compound Danshen Dripping Pills, and a proposed consumer-health joint venture with Herbalife announced in 2017. The company’s international activities are intended to connect Chinese medicine research and manufacturing capabilities with foreign regulatory, scientific and distribution networks. The wider Tasly group has historically operated beyond prescription and hospital medicines. Its broader health platform has included functional foods, health-management services, medical and rehabilitation services, botanical products, tea-based products, mineral water and other consumer-health businesses. The group has also owned or invested in non-pharmaceutical businesses, including Guotai liquor and Yunnan tea operations. This broader structure is reflected in Tasly’s use of concepts such as “great health,” digital health and intelligent health services, although the Shanghai-listed pharmaceutical company remains the core public pharmaceutical asset. A significant ownership transition occurred in 2025. China Resources Sanjiu acquired a 28% interest from Tasly’s former controlling shareholders, and the transaction completed on March 27, 2025. Tasly consequently became a non-wholly-owned subsidiary of China Resources Sanjiu and, through it, part of the China Resources group. The transaction also produced changes to the listed company’s board and senior management. Following the change, Cai Jinyong became chairman and general manager, while Xi Kai became a worker director and general manager of the company’s operating structure. Tasly’s present positioning therefore combines three elements: a listed pharmaceutical manufacturer, a recognized modern-TCM platform and a broader life-and-health group undergoing integra… A major strategic theme has been the modernization and internationalization of traditional Chinese medicine. Tasly has invested in research facilities, clinical studies, manufacturing capacity, and regulatory filings to bring selected traditional formulations closer to evidence-based pharmaceutical standards. Its international work has included development activities in the United States and other markets, though regulatory progress and commercial availability have varied by jurisdiction. Compound Danshen Dripping Pills became a prominent example of both the opportunities and difficulties facing traditional Chinese medicines seeking approval through modern foreign drug-approval systems. Tasly was historically a Shanghai-listed company under ticker 600535. Public reporting has also described changes in the relationship between the listed pharmaceutical company and Tasly Holding Group, including ownership and privatization-related developments. In 2025, a 28% share transfer completed on March 27 made China Resources Sanjiu the controlling shareholder, turning Tasly into a non-wholly-owned subsidiary within the China Resources pharmaceutical system; Cai Jinyong became chairman and general manager. Because the exact current listing and ownership status may change with corporate transactions, the latest exchange announcements should be consulted before treating the company as a current public-market reference.

Tasly Pharmaceutical was established in Tianjin in 1994 by Yan Xijun and developed as the pharmaceutical arm of the wider Tasly healthcare group. Its formation occurred during a period in which Chinese pharmaceutical companies were increasingly adopting corporate branding, industrial production, modern quality management, and proprietary research while continuing to draw on traditional medical knowledge. The company's early identity was built around traditional Chinese medicines produced in standardized pharmaceutical forms. This model differed from informal herbal practice by emphasizing controlled manufacturing, branded packaging, dosage consistency, extraction technology, and formal distribution. Tasly's growth helped make it a visible example of the modernization of traditional Chinese medicine in the Chinese pharmaceutical market. Compound Danshen Dripping Pills became the company's best-known product. The medicine is based on a traditional cardiovascular formulation and uses a dripping-pill dosage form associated with Tasly's product identity. Its commercial importance also gave the company a platform for research and overseas regulatory work. Tasly sought to support the product with clinical evidence and to pursue approval in international markets, particularly through the regulatory framework of the United States. These efforts illustrated both the potential of traditional Chinese medicines to enter global pharmaceutical markets and the difficulty of satisfying regulatory requirements designed primarily around conventional drug-development models. Over time, Tasly expanded its pharmaceutical activities beyond the flagship cardiovascular product. The portfolio has included traditional Chinese medicines, chemical drugs, over-the-counter products, health-related products, and research programs involving botanical and natural compounds. The wider Tasly group has operated across multiple healthcare-related sectors, but the pharmaceutical company has remained associated with branded medicines and the industrial presentation of Chinese medical formulations. Tasly also became connected with China's public capital markets. The pharmaceutical business was historically listed on the Shanghai Stock Exchange under ticker 600535. Corporate restructuring and ownership developments involving Tasly Holding Group and the listed pharmaceutical entity have affected how the company should be described as a public company. Since those arrangements may change over time, current listing status should be checked in the latest Shanghai Stock Exchange disclosures and corporate announcements. In strategic terms, Tasly's history reflects three connected ambitions: to turn traditional formulations into standardized commercial medicines, to build a research and manufacturing platform rather than rely only on heritage branding, and to make selected products acceptable to overseas regulators and healthcare professionals. The company remains a significant reference point for the commercialization of traditional Chinese medicine, although the scale of its international business and the current structure of its listed entity require verification from up-to-date sources. Tasly was established in Tianjin in 1994 under the leadership of Yan Xijun. Its development took place during the restructuring and modernization of China’s pharmaceutical industry, when companies sought to transform traditional Chinese medicine from relatively localized preparations into standardized, scalable, and commercially managed pharmaceutical products. The company built its identity around proprietary Chinese medicines and the integration of traditional formulations with contemporary pharmaceutical manufacturing. This approach involved greater attention to raw-material control, extraction technology, dosage-form engineering, production standards, quality assurance, and clinical development. Among the products most closely associated with the Tasly name is Compound Danshen Dripping Pills, a cardiovascular medicine formulated from traditional Chinese medicinal ingredients and delivered as orally administered dripping pills. The product became an important commercial and strategic asset because it represented a modern pharmaceutical presentation of a traditional formula. During its expansion, Tasly developed capabilities spanning research, manufacturing, distribution, and healthcare-related business activities. The group broadened its portfolio beyond traditional Chinese medicines to include chemical pharmaceuticals, biological products, health products, and other medical or wellness businesses. This diversification reflected both the expanding scope of China’s healthcare market and the company’s effort to reduce dependence on a single product category. Tasly also pursued international development for selected products. The most visible international effort concerned Compound Danshen Dripping Pills and attempts to obtain regulatory acceptance in overseas markets. These efforts required clinical and manufacturing evidence suited to the standards of the relevant regulators. The process illustrated the difficulty of translating a traditional medicine product into a conventional international pharmaceutical-approval framework, where efficacy, safety, consistency, and trial design are assessed under jurisdiction-specific rules. The Tasly corporate structure has included listed pharmaceutical operations and a broader group of healthcare-related enterprises. As a result, public references may use “Tasly,” “Tasly Pharmaceutical Group,” or names of individual subsidiaries and product businesses in ways that do not always distinguish a standalone “Tasly Medical” brand from the wider organization. The available information supports identifying Tasly Medical with the pharmaceutical and healthcare activities of the Tasly group, but does not establish a separate legal entity with that exact English name. In the contemporary Chinese market, Tasly is associated with proprietary medicines, traditional Chinese medicine modernization, pharmaceutical manufacturing, and healthcare diversification. Its historical importance is less that it created traditional Chinese medicine itself than that it helped package selected traditional formulations within a modern corporate, industrial, and regulatory system. The company’s continuing relevance depends on the performance of its established medicines, the development of new pharmaceutical products, the regulation of traditional Chinese medicine, and the group’s ability to expand beyond its domestic base. Tasly Group was established in Tianjin in 1994 under the leadership of Yan Xijun. Its early development was tied to the commercial production and distribution of proprietary traditional Chinese medicines. Rather than presenting traditional medicine solely as an artisanal or local practice, Tasly pursued industrial-scale manufacturing, branded packaging, standardized dosage forms, and broader pharmaceutical distribution. A central part of the group's development was its focus on modernizing traditional formulations. This approach involved investment in extraction and formulation technologies, pharmaceutical production systems, quality controls, and research intended to make traditional medicines more consistent and easier to distribute. Compound Danshen Dripping Pill became the most recognizable example of this strategy. The product's prominence helped give Tasly a distinct corporate identity within China's traditional Chinese medicine industry and provided a basis for the group's international ambitions. During its expansion, Tasly broadened its activities beyond a narrow proprietary-medicine portfolio. The group became associated with prescription drugs, over-the-counter medicines, health foods, nutritional products, biotechnology and drug research, medicinal-material sourcing, and healthcare services. This diversification reflected a common strategy among large Chinese healthcare groups: combine regulated pharmaceutical businesses with consumer-health and service businesses while maintaining a recognizable corporate brand. Tasly's corporate history also includes the development of publicly traded pharmaceutical operations. Tasly Pharmaceutical Group Co., Ltd. became a significant listed company associated with the Tasly name, while the wider group continued to operate as a broader holding and business platform. The listed-company relationship means that references to Tasly in financial or pharmaceutical reporting may refer either to the group brand or to a specific subsidiary, and those entities should not automatically be treated as identical. The group subsequently emphasized research, intellectual property, manufacturing capacity, and international registration. Compound Danshen Dripping Pill was developed as a product that could be evaluated under modern drug-regulatory frameworks, including overseas clinical and registration processes. These efforts illustrated both the opportunity and difficulty of exporting traditional Chinese medicines: products required evidence, consistent raw materials, pharmaceutical-grade production, and compliance with the rules of each target market. Tasly has continued to present itself as an integrated healthcare organization combining traditional Chinese medicine with modern pharmaceutical science. Its businesses and priorities have evolved with changes in China's healthcare regulation, pharmaceutical-market competition, and the distinction between medicines, health foods, and wellness products. Because the group has operated through multiple entities and its leadership and portfolio have changed over time, current corporate details require verification from recent official disclosures. The enduring brand theme, however, is the industrial and scientific modernization of traditional Chinese medicine within a diversified healthcare group. Tasly was established in Tianjin in 1994 by Yan Xijun. Its early development centered on the idea that traditional Chinese medicine could be industrialized through modern pharmaceutical technology, standardized production and evidence-oriented research. The company’s initial identity was therefore different from that of a conventional herbal-products seller: it sought to create reproducible dosage forms and scalable manufacturing systems for TCM-derived medicines. Compound Danshen Dripping Pills became the company’s signature product and a major vehicle for its modernization strategy. The dripping-pill dosage form helped Tasly build a recognizable commercial franchise in cardiovascular medicine while also giving the company a product around which it could organize manufacturing technology, quality control, clinical research and international regulatory work. Tasly later developed a broader modern-TCM portfolio that included Yangxue Qingnao products, Qishen Yiqi Dripping Pills and Yiqi Fumai for Injection. Tasly expanded its corporate scope during the late 1990s and early 2000s. The group entered additional consumer and health-related businesses, acquired or established operations outside its core pharmaceutical activity and developed a more diversified holding-company structure. In 2002, the pharmaceutical company was listed on the Shanghai Stock Exchange. The listing supplied a public-capital platform for manufacturing expansion, research facilities and further product development. The company’s internationalization effort became more visible in the 2000s. Tasly Pharmaceuticals, Inc. was established in Rockville, Maryland, in 2006. The United States entity was designed to support clinical research, regulatory submissions, scientific evaluation, technical cooperation, brand promotion and overseas market development. Compound Danshen Dripping Pills entered an FDA-centered development pathway, receiving an investigational new drug-related milestone in 1997, passing Phase II clinical trials in 2010 and later reaching Phase III development. In 2015, Tasly also agreed to cooperate with Arbor Pharmaceuticals on the research and marketing of T89 in the United States. Alongside modern TCM, Tasly built a biomedical and chemical-drug platform. Tasly Bio-pharmaceutical Co., Ltd. was founded in 2001 and developed capabilities spanning research, manufacturing and commercialization. The group’s products and pipeline came to include recombinant human prourokinase for injection, chemical medicines such as temozolomide, eszopiclone and tadalafil, and additional candidates in cardiovascular, oncology, autoimmune, digestive and metabolic fields. The company described its research model as a combination of independent research, cooperative research, product introduction, acquisition and commercialization investment. Tasly’s production and research infrastructure expanded during the 2010s. The group began construction of its Huai’an biomedical industrial park in 2010, established or developed additional manufacturing and research sites, and received approvals connected with a national key laboratory for innovative Chinese medicine and a state-local joint engineering laboratory. The company presented these facilities as part of a broader effort to connect formulation science, raw-material traceability, intelligent manufacturing, clinical evidence and international regulatory requirements. The group also pursued a broader “great health” strategy. Its activities extended into functional foods, botanical materials, tea products, mineral water, health management, medical services, rehabilitation and other consumer-health categories. Guotai liquor and Yunnan tea became notable non-pharmaceutical businesses within the wider Tasly ecosystem. This diversification created a corporate house broader than the listed pharmaceutical company itself, while the pharmaceutical business remained the group’s most important public-market identity. Tasly’s development was accompanied by controversy. In 2009, pharmacologist Li Lianda publicly questioned the safety of a key Tasly product. Tasly brought a lawsuit against Li in 2013, arguing that the allegation was unfounded and influenced by his relationships with Guangzhou Pharmaceutical, a competitor. In September 2014, the Tianjin High People’s Court ruled in Tasly’s favor and ordered Li to apologize and pay CNY 300,000. The episode remains the principal scandal or legal controversy associated with the Tasly article in English-language reference material. In 2017, Tasly and Herbalife announced plans for a United States joint venture, HT Innovations LP. The proposed venture was intended to combine Tasly’s formulations, patents and clinical work with Herbalife’s scientific, regulatory and distribution capabilities. The announcement illustrated Tasly’s interest in international consumer health, although the available reference material does not establish that the proposed structure became a major operating business. A major structural change came in 2024 and 2025. China Resources Sanjiu agreed to acquire a 28% stake in Tasly Pharmaceutical from the former controlling shareholders. The share transfer was completed on March 27, 2025, making Tasly a non-wholly-owned subsidiary of China Resources Sanjiu and, through the China Resources group, part of a large state-owned pharmaceutical ecosystem. Former controlling shareholders and several directors departed, while a new board and senior-management team was appointed. Cai Jinyong became chairman and general manager, and the company’s operating priorities became more closely integrated with China Resources Sanjiu’s pharmaceutical platform. In its current form, Tasly combines a long-established modern-TCM franchise with biopharmaceutical and chemical-drug capabilities. It continues to emphasize cardiovascular and metabolic disease, digestive disease, oncology and immunology, and neurological or psychiatric conditions. Its corporate narrative now places greater weight on full-course health management, digital empowerment, intelligent manufacturing and integration with the wider China Resources health-care portfolio. Tasly’s history is consequently one of transformation: from a Tianjin modern-TCM pioneer into a listed, diversified pharmaceutical company and ultimately a controlled subsidiary within a major state-owned health-care group. Tasly also became connected with China's public capital markets. The pharmaceutical business was historically listed on the Shanghai Stock Exchange under ticker 600535. Corporate restructuring and ownership developments involving Tasly Holding Group and the listed pharmaceutical entity have affected how the company should be described as a public company. In 2025, a 28% share transfer completed on March 27 made China Resources Sanjiu the controlling shareholder, turning Tasly into a non-wholly-owned subsidiary within the China Resources pharmaceutical system; Cai Jinyong became chairman and general manager. Since those arrangements may change over time, current listing status should be checked in the latest Shanghai Stock Exchange disclosures and corporate announcements.

• 2025

  China Resources Sanjiu became Tasly’s controlling shareholder

  [12]China Resources Pharmaceutical Group announcement on completion of Tasly acquisitionhkexnews.hk

  A 28% share transfer completed on March 27, 2025, making Tasly a non-wholly-owned subsidiary of China Resources Sanjiu and changing its board and senior management.

• 2024

  Tasly celebrated its thirtieth anniversary

  [18]Tasly celebrated its thirtieth anniversaryen.tasly.com

  The group marked three decades of operations and presented its evolution toward a broader life-and-health platform.

• 2017

  Tasly and Herbalife announced a proposed joint venture

  [14]Herbalife announcement on proposed HT Innovations joint ventureir.herbalife.com

  The proposed HT Innovations LP was intended to develop and commercialize consumer-health products for international markets.

• 2016

  Compound Danshen Dripping Pills passed FDA Phase III trials

  [8]Tasly Holding Group company profile and historyen.tasly.com

  Tasly reported completion of Phase III clinical development for the product in the FDA-centered United States program.

• 2015

  Tasly established a major innovative-TCM research platform

  [17]Compound Danshen Dripping Pills entered the FDA development pathwaytaslypharma.com

  The company received approvals connected with a national key laboratory and a state-local joint engineering laboratory focused on innovative Chinese medicine.

• 2015

  Tasly and Arbor Pharmaceuticals agreed to cooperate on T89

  [9]Tasly Pharmaceutical Group company profileen.taslypharma.com

  The parties agreed to cooperate on research and marketing of Compound Danshen Dripping Pills in the United States.

• 2014

  Tasly expanded North American operations

  [17]Compound Danshen Dripping Pills entered the FDA development pathwaytaslypharma.com

  The company formally launched North American operations as part of its internationalization strategy.

• 2011

  Recombinant human prourokinase was launched

  [8]Tasly Holding Group company profile and historyen.tasly.com

  Tasly launched rhPro-UK, a biological thrombolytic product described by the company as a national Class I new medicine.

• 2010

  Compound Danshen Dripping Pills passed FDA Phase II trials

  [17]Compound Danshen Dripping Pills entered the FDA development pathwaytaslypharma.com

  Tasly reported completion of Phase II clinical development for its leading modern-TCM product in the United States.

• 2006

  Tasly Pharmaceuticals, Inc. was established in the United States

  [11]Tasly Holding Group member companies and international platformen.tasly.com

  The Rockville, Maryland subsidiary was created to support overseas clinical research, regulatory affairs, technical cooperation and market development.

Showing the 10 most recent.

A modern Chinese pharmaceutical brand that industrializes and standardizes traditional Chinese medicine while pursuing evidence-based research and international regulatory acceptance. A Chinese pharmaceutical and healthcare brand positioned around the modernization, industrial production, research, and commercialization of traditional Chinese medicine, with additional activities in conventional pharmaceuticals and broader health products. A Chinese healthcare group positioned around the modernization of traditional Chinese medicine, supported by pharmaceutical research, standardized manufacturing, consumer health products, and medical services. A modern-TCM and biomedical pharmaceutical platform that combines standardized traditional Chinese medicine, innovative biopharmaceuticals, chemical drugs and integrated health services. A modern Chinese pharmaceutical brand that industrializes and standardizes traditional Chinese medicine while pursuing evidence-based research and international regulatory acceptance, with additional activities in conventional pharmaceuticals, biopharmaceuticals, and broader health products.

• Traditional Chinese cardiovascular medicine

  Compound Danshen Dripping Pills (Dantonic; T89)

  Compound Danshen Dripping Pills are Tasly's signature medicine and are derived from a traditional Chinese formulation associated with cardiovascular care. The product uses a dripping-pill dosage form and has been marketed in China for indications related to coronary heart disease and angina. Tasly has also supported the product with modern manufacturing, clinical research, and international regulatory-development programs, including an FDA-centered clinical program, cooperation with overseas pharmaceutical companies such as Arbor Pharmaceuticals, and marketing under the Dantonic name internationally. Its importance extends beyond sales: it serves as the company's principal example of how a traditional formulation can be standardized, branded, and evaluated through contemporary pharmaceutical processes. A cardiovascular traditional Chinese medicine associated with Tasly and formulated from traditional medicinal ingredients. Its dripping-pill dosage form and industrial manufacturing were central to Tasly’s strategy of presenting a traditional formulation through a standardized modern pharmaceutical product. The medicine has been marketed primarily in China and has also been the focus of international clinical and regulatory development efforts. Compound Danshen Dripping Pill is Tasly's best-known proprietary Chinese medicine. It is associated with cardiovascular applications in China and is formulated as a dripping pill rather than a conventional tablet or decoction. The product has been central to Tasly's brand-building and internationalization strategy because the group has sought to support a traditional formulation with standardized manufacturing, quality controls, and modern clinical and regulatory evidence. Tasly’s signature product is a dripping-pill formulation derived from traditional Chinese medicine and positioned primarily for cardiovascular indications. It has served as the company’s main internationalization vehicle, with an FDA-centered clinical and regulatory program, multiple stages of clinical development and cooperation with overseas pharmaceutical companies. The product is also marketed internationally under the Dantonic name and is central to Tasly’s reputation as a modern-TCM manufacturer.

• Traditional Chinese medicines

  Tasly traditional Chinese medicine portfolio

  Tasly's broader traditional Chinese medicine portfolio includes branded formulations manufactured in standardized pharmaceutical forms. The company has emphasized controlled production, quality systems, dosage consistency, and research support as ways to distinguish industrial products from unstandardized herbal preparations. Specific products and indications vary across the company's portfolio and markets.

• Pharmaceuticals

  Chemical and conventional pharmaceutical products

  In addition to traditional Chinese medicines, Tasly has operated in conventional pharmaceutical categories, including prescription and over-the-counter medicines, as well as chemical and biological products. These products form part of the company's broader effort to operate as a diversified pharmaceutical manufacturer rather than as a single-product traditional-medicine business.

• Traditional Chinese medicine

  Tasly proprietary Chinese medicines

  Tasly’s broader proprietary Chinese medicine portfolio includes standardized medicines derived from traditional formulations. These products form the historical and commercial foundation of the group’s pharmaceutical identity and are supported by manufacturing, quality-control, distribution, and clinical-development capabilities. This portfolio comprises branded traditional Chinese medicines manufactured and marketed through Tasly-associated pharmaceutical operations. Products have included medicines in cardiovascular and other therapeutic areas, with formulations presented in modern dosage forms and produced through industrial pharmaceutical processes. Individual products, indications, and availability vary by market and by operating subsidiary.

• Pharmaceuticals

  Chemical and biological pharmaceuticals

  In addition to traditional Chinese medicines, the wider Tasly pharmaceutical organization has developed or marketed chemical medicines and biological products. These activities reflect the group’s effort to operate across multiple pharmaceutical technologies rather than remain limited to traditional formulations.

• Consumer healthcare

  Tasly health and nutritional products

  Tasly has also operated in health foods, nutrition, and wellness-related consumer products. These offerings extend the brand beyond prescription and proprietary medicines and are generally positioned around preventive health, nutrition, or everyday wellness. Regulatory classification and product availability differ across jurisdictions, so consumer-health products should be distinguished from approved medicines.

• Modern traditional Chinese medicine

  Yangxue Qingnao Granules and Pills

  Yangxue Qingnao is part of Tasly's modernized Chinese-medicine portfolio. The company markets the granule and pill forms within its neurological and circulation-related product offerings. The line illustrates Tasly's approach of converting classical or traditional therapeutic concepts into standardized industrial dosage forms for domestic pharmaceutical distribution.

• Modern traditional Chinese medicine

  Qishen Yiqi Dripping Pills

  Qishen Yiqi Dripping Pills are included in Tasly's cardiovascular modern-TCM portfolio. The product uses the group's characteristic dripping-pill technology and forms part of the company's effort to build differentiated products around cardiovascular and metabolic disease. It is one of the principal modern Chinese formulae cited in Tasly's corporate product materials.

• Modern traditional Chinese medicine

  Yiqi Fumai for Injection

  Yiqi Fumai for Injection, supplied in a freeze-dried formulation, is one of Tasly's modernized Chinese-medicine products for hospital and clinical use. Its inclusion alongside dripping pills demonstrates the company's broader dosage-form capabilities, extending from oral and rapidly dissolving products to injectable preparations.

• Biopharmaceutical · 2011

  Recombinant human prourokinase for injection (rhPro-UK)

  Recombinant human prourokinase is a biological thrombolytic medicine developed and commercialized by Tasly. The company describes it as a national Class I biological new medicine and launched it in 2011. It represents Tasly's move beyond traditional Chinese medicine into recombinant biologics and cardiovascular emergency treatment.

• Chemical pharmaceutical

  Temozolomide

  Temozolomide is a chemical oncology medicine included in Tasly's pharmaceutical portfolio. Its presence gives the company exposure to conventional small-molecule cancer treatment in addition to its modern-TCM and biological-drug businesses. Tasly identifies oncology as one of its principal therapeutic priorities.

• Chemical pharmaceutical

  Eszopiclone tablets

  Eszopiclone tablets are part of Tasly's chemical-drug portfolio and support the company's activity in central-nervous-system and sleep-related treatment categories. The product is cited by Tasly as an example of its ability to commercialize conventional chemical medicines alongside innovative TCM and biopharmaceutical products.

• Chemical pharmaceutical

  Tadalafil

  Tadalafil is another chemical medicine cited in Tasly's corporate product materials. Its inclusion reflects the breadth of the listed pharmaceutical company's portfolio beyond the cardiovascular and traditional-medicine products most closely associated with the Tasly brand.

• Consumer health product

  Deepure biological tea products

  Deepure is associated with Tasly's broader health and lifestyle activities, particularly tea-based consumer products and biological tea processing. The business links botanical raw materials, processing technology and wellness-oriented consumption, illustrating the wider group's "great health" strategy beyond prescription medicines.

• Consumer health product

  C-Cell Vitality mineral water

  C-Cell Vitality is a mineral-water product described in Tasly group materials as being sourced from underground springs in Jilin and marketed with technology and mineral-content claims. It belongs to the broader Tasly Holding Group rather than the core listed pharmaceutical portfolio.

• 2017

  FDA clinical trial results for Compound Danshen Dripping Pills spark controversy

  In 2017, Li Lianda published an article questioning the results of Tasly's U.S. Phase III clinical trial of Compound Danshen Dripping Pills. The company publicly rebutted this, saying that some statistical indicators were significant, and stated that it would supplement confirmatory trials to meet application requirements. This entry records the controversy over interpretation of the trial results and does not treat the critical article as an FDA negative ruling.

  Source

• 2014

  Litigation over safety criticism of a Tasly product

  Pharmacologist Li Lianda criticized the safety of a key Tasly product in 2009. Tasly sued him in 2013, alleging that the criticism was baseless and influenced by financial and employment relationships with Guangzhou Pharmaceutical. In September 2014, the Tianjin High People's Court ruled in Tasly's favor and ordered Li to apologize and pay CNY 300,000 in compensation.

  Source

Read more

• 2024Tasly 30th anniversary program

  China · International

  Tasly marked its thirtieth anniversary with internal and public-facing activities emphasizing its development from a modern-TCM enterprise into a diversified life-and-health group. The anniversary reinforced the group's corporate narrative around innovation, intelligent manufacturing, globalization and integrated health.

  Outcome. The anniversary reinforced the group’s corporate narrative around innovation, intelligent manufacturing, globalization and integrated health.

  Source
• 2024ESG and intelligent-manufacturing positioning

  China

  Tasly promoted environmental management, social responsibility, governance and intelligent manufacturing as part of its corporate reputation and industrial-development program. The company reported ESG-oriented recognition at the 2024 China International Fair for Trade in Services and continued to present smart manufacturing as a strategic capability.

  Outcome. The company reported ESG-oriented recognition at the 2024 China International Fair for Trade in Services and continued to present smart manufacturing as a strategic capability.

  Source
• 2017HT Innovations LP with Herbalife

  United States · International

  Tasly and Herbalife announced a proposed joint venture intended to develop and commercialize consumer-health products. The plan was designed to combine Tasly’s formulations, patents and clinical research with Herbalife’s scientific, regulatory and global distributor network. Tasly and Herbalife announced a proposed joint venture intended to develop and commercialize consumer-health products. The plan was designed to combine Tasly's formulations, patents and clinical research with Herbalife's scientific, regulatory and global distributor network. The available announcement describes a proposed structure and expected regulatory approvals but does not establish a significant subsequent operating outcome.

  Outcome. The available announcement describes a proposed structure and expected regulatory approvals but does not establish a significant subsequent operating outcome.

  Source
• 2015T89 international development and Arbor cooperation

  United States · North America

  Tasly used Compound Danshen Dripping Pills’ international development code, T89, as a platform for overseas research and commercialization. A cooperation agreement with Arbor Pharmaceuticals supported research and marketing planning in the United States. Tasly used Compound Danshen Dripping Pills' international development code, T89, as a platform for overseas research and commercialization. A cooperation agreement with Arbor Pharmaceuticals supported research and marketing planning in the United States. Tasly subsequently reported completion of Phase III clinical development for Compound Danshen Dripping Pills in 2016, although the reference materials do not establish final United States approval.

  Outcome. Tasly subsequently reported completion of Phase III clinical development for Compound Danshen Dripping Pills in 2016, although the reference materials do not establish final United States approval.

  Source

• 2025

  Accept China Resources Sanjiu as controlling shareholderM&A

  Background

  Tasly’s former controlling shareholders agreed to transfer 28% of the listed pharmaceutical company to China Resources Sanjiu. The transaction formed part of a broader China Resources pharmaceutical consolidation strategy.

  Action taken

  The share transfer was completed on March 27, 2025. China Resources Sanjiu became the controlling shareholder, and Tasly became a non-wholly-owned subsidiary. The transaction was associated with changes to the board, supervisory bodies and senior management.

  Aftermath

  Cai Jinyong became chairman and general manager, while China Resources became Tasly’s ultimate controlling system. The listed company retained its Shanghai listing and ticker 600535.SS.

  Consideration for the transferred 28% stake. CNY 6,073,803,149.04 after adjustment; originally CNY 6,211,844,129.70 before specified dividend-related adjustments (Transaction announced in 2024; completed March 27, 2025)

  Source

• 2017

  Propose a joint venture with HerbalifeM&A

  Background

  Tasly sought to pair its modern-TCM formulations, patents and clinical research with Herbalife’s scientific, regulatory and international distribution capabilities.

  Action taken

  The parties announced plans for HT Innovations LP in the United States to develop and commercialize consumer-health products.

  Aftermath

  The announcement described the venture as subject to regulatory approval. The available sources do not provide sufficient evidence to characterize the venture’s long-term operating results.

  Source

• 2015

  Deepen international development of T89Strategy

  Background

  Compound Danshen Dripping Pills was Tasly’s leading modern-TCM product and the principal vehicle for entering international pharmaceutical markets.

  Action taken

  Tasly cooperated with Arbor Pharmaceuticals on research and marketing of T89 in the United States and continued the product’s FDA-centered clinical program.

  Aftermath

  Tasly reported that the product passed Phase III clinical trials in 2016. The available materials do not confirm final United States marketing authorization.

  Source

• 2006

  Establish a United States international platformStrategy

  Background

  Tasly needed a dedicated overseas structure to manage clinical research, regulatory interaction, technical cooperation and international business development.

  Action taken

  The group established Tasly Pharmaceuticals, Inc. in Rockville, Maryland.

  Aftermath

  The subsidiary became Tasly’s stated overseas headquarters and a platform for internationalization of its pharmaceutical portfolio.

  Source

• 2002

  Use public-market capital to scale the pharmaceutical businessStrategy

  Background

  Tasly was expanding manufacturing and research capabilities around modern TCM and needed a listed corporate platform.

  Action taken

  Tasly Pharmaceutical Group listed on the Shanghai Stock Exchange on August 23, 2002, under code 600535.

  Aftermath

  The listing established Tasly as a public pharmaceutical company and provided the foundation for subsequent investment, product development and corporate expansion.

  Source

• Pursuit of international approval for a traditional Chinese medicineStrategy

  Background

  Tasly sought to support Compound Danshen Dripping Pills with international clinical and regulatory evidence rather than limiting the product to the Chinese market.

  Action taken

  The company conducted overseas development and engaged with regulators and research partners to pursue a modern drug-approval pathway.

  Aftermath

  The program made Compound Danshen Dripping Pills one of the most visible attempts to bring a traditional Chinese medicine into a highly regulated international pharmaceutical system, although final regulatory outcomes have differed by jurisdiction.

  Source

• Corporate restructuring involving the listed pharmaceutical entityM&A

  Background

  Tasly's historical Shanghai listing and its relationship with Tasly Holding Group have been affected by ownership and restructuring developments.

  Action taken

  The relevant entities pursued changes to ownership and corporate structure, with the precise current status requiring confirmation from the latest exchange filings.

  Aftermath

  Tasly Pharmaceutical should not automatically be treated as an independently listed company without checking current Shanghai Stock Exchange and company disclosures.

  Source

• Modernization and internationalization of traditional Chinese medicineStrategy

  Background

  Tasly built its pharmaceutical identity around converting selected traditional Chinese medicine formulas into standardized, industrially manufactured dosage forms supported by modern quality systems and clinical development. Tasly sought to make traditional Chinese medicine more compatible with large-scale pharmaceutical manufacturing and international regulatory expectations.

  Action taken

  The group invested in pharmaceutical research, manufacturing, quality control, distribution, and regulatory development while retaining traditional medicine as a core commercial category. The group invested in standardized dosage forms, manufacturing controls, research, clinical evaluation, and overseas regulatory programs, using Compound Danshen Dripping Pill as a prominent example.

  Aftermath

  This strategy made Tasly one of the Chinese companies most closely associated with the modernization and commercialization of proprietary traditional Chinese medicines. The strategy strengthened Tasly's identity as a modern traditional-Chinese-medicine company, while overseas commercialization remained dependent on country-specific evidence and regulatory requirements.

• International development of a traditional medicine productStrategy

  Background

  Tasly sought to develop overseas regulatory acceptance for Compound Danshen Dripping Pills, requiring evidence compatible with international pharmaceutical standards.

  Action taken

  The company pursued international clinical and regulatory work for the product rather than limiting its development to the domestic Chinese market.

  Aftermath

  The effort highlighted both the international potential of standardized traditional medicines and the scientific, clinical, and regulatory challenges involved in obtaining approval outside China.

• 2025

  Tasly Pharmaceutical became a non-wholly-owned subsidiary of China Resources Sanjiu[12]China Resources Pharmaceutical Group announcement on completion of Tasly acquisitionhkexnews.hk

  Leadership change · M&A

  The transfer of 28% of Tasly Pharmaceutical’s shares to China Resources Sanjiu was completed on March 27, 2025. The transaction changed the listed company’s controlling shareholder and ultimate controller and led to board and senior-management changes.

• 2025

  Tasly reported 2024 revenue of CNY 8.498 billion[9]Tasly Pharmaceutical Group company profileen.taslypharma.com

  Other

  Tasly’s 2024 company materials reported revenue of CNY 8.498 billion and non-IFRS net profit of CNY 1.069 billion for the 2024 reporting period.

• 2024

  Tasly received ESG-oriented management recognition at CIFTIS[18]Tasly celebrated its thirtieth anniversaryen.tasly.com

  Other

  Tasly Pharma Group was recognized at the 2024 China International Fair for Trade in Services for its environmental, social and governance management practices.

• 2024

  Tasly marked its 30th anniversary[18]Tasly celebrated its thirtieth anniversaryen.tasly.com

  Campaign · Other

  The group held anniversary activities in May 2024, presenting the milestone as a review of its development from a modern-TCM enterprise into a broader life-and-health group.

• 2024

  Tasly was included in 2024 private-enterprise rankings[18]Tasly celebrated its thirtieth anniversaryen.tasly.com

  Other

  Tasly reported inclusion in 2024 national private-business and private-manufacturer rankings, reflecting the broader group’s continuing visibility in China’s private-sector economy.

• 2017

  Tasly and Herbalife announced a proposed United States joint venture[14]Herbalife announcement on proposed HT Innovations joint ventureir.herbalife.com

  M&A · Other

  Tasly and Herbalife announced plans for HT Innovations LP, intended to develop and commercialize consumer-health products using Tasly formulations and research alongside Herbalife’s scientific, regulatory and international distribution capabilities.

• 2016

  Compound Danshen Dripping Pills completed FDA Phase III clinical trials[8]Tasly Holding Group company profile and historyen.tasly.com

  Product generation

  Tasly reported that Compound Danshen Dripping Pills had passed Phase III clinical trials in the United States development program.

• 2015

  Tasly and Arbor Pharmaceuticals agreed to cooperate on T89[9]Tasly Pharmaceutical Group company profileen.taslypharma.com

  Product launch

  Tasly entered into a cooperation arrangement with United States-based Arbor Pharmaceuticals concerning research and marketing of T89, the international development designation for Compound Danshen Dripping Pills.

• 2014

  Tasly expanded its North American operations[17]Compound Danshen Dripping Pills entered the FDA development pathwaytaslypharma.com

  Other

  Tasly officially launched operations in North America, building on its United States regulatory, clinical and business-development platform.

• 2011

  Tasly’s recombinant human prourokinase product was launched[8]Tasly Holding Group company profile and historyen.tasly.com

  Product launch

  Tasly released recombinant human prourokinase for injection, described by the company as a national Class I biological thrombolytic medicine.

Showing the 10 most recent.

1. 1Tasly official corporate websitetasly.com
2. 2Shanghai Stock Exchangesse.com.cn
3. 3U.S. Food and Drug Administrationfda.gov
4. 4天士力集团tasly.com
5. 5天士力集团tasly.com
6. 6天士力集团tasly.com
7. 7Tasly, English Wikipedia articleen.wikipedia.org
8. 8Tasly Holding Group company profile and historyen.tasly.com
9. 9Tasly Pharmaceutical Group company profileen.taslypharma.com
10. 10Tasly Group leadership and founder profiletasly.com
11. 11Tasly Holding Group member companies and international platformen.tasly.com
12. 12China Resources Pharmaceutical Group announcement on completion of Tasly acquisitionhkexnews.hk
13. 13Tasly 2025 interim reportbig5.sse.com.cn
14. 14Herbalife announcement on proposed HT Innovations joint ventureir.herbalife.com
15. 15China Resources Sanjiu transaction materialsstatic.cninfo.com.cn
16. 16https://www.tasly.comtasly.com
17. 17Compound Danshen Dripping Pills entered the FDA development pathwaytaslypharma.com
18. 18Tasly celebrated its thirtieth anniversaryen.tasly.com
19. 19FDA clinical trial results for Compound Danshen Dripping Pills spark controversyhealth.people.com.cn
20. 20天士力剥离高负债资产聚焦“医药工业” 主力遭遇天花板_个股资讯_市场_中金在线sc.stock.cnfol.com